Golimumab Completed Phase 4 Trials for Ulcerative Colitis Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03124121Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
NCT02092285Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
NCT02155335Preference for a Prefilled Syringe or Smartjectâ„¢ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)